Lilly Eli & Co’s (NYSE:LLY) Sentiment is 1.1

April 25, 2018 - By Vivian Park

Eli Lilly and Company (NYSE:LLY) Logo

Sentiment for Lilly Eli & Co (NYSE:LLY)

Lilly Eli & Co (NYSE:LLY) institutional sentiment increased to 1.1 in 2017 Q4. Its up 0.21, from 0.89 in 2017Q3. The ratio increased, as 463 investment managers started new and increased stock positions, while 422 cut down and sold stakes in Lilly Eli & Co. The investment managers in our partner’s database now have: 827.08 million shares, down from 827.83 million shares in 2017Q3. Also, the number of investment managers holding Lilly Eli & Co in their top 10 stock positions decreased from 19 to 15 for a decrease of 4. Sold All: 42 Reduced: 380 Increased: 346 New Position: 117.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide. The company has market cap of $85.61 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It currently has negative earnings. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

The stock increased 2.58% or $2.07 during the last trading session, reaching $82.16. About 1.22 million shares traded. Eli Lilly and Company (NYSE:LLY) has declined 10.19% since April 25, 2017 and is downtrending. It has underperformed by 21.74% the S&P500.

Lilly Endowment Inc holds 100% of its portfolio in Eli Lilly and Company for 123.08 million shares. Private Capital Advisors Inc. owns 385,549 shares or 11.31% of their US portfolio. Moreover, Weatherly Asset Management L. P. has 6.69% invested in the company for 327,825 shares. The Sweden-based Healthinvest Partners Ab has invested 5.7% in the stock. Valueworks Llc, a New York-based fund reported 69,752 shares.

Since January 1, 0001, it had 0 insider buys, and 8 selling transactions for $21.75 million activity.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Ratings analysis reveals 45% of Eli Lilly & Co’s analysts are positive. Out of 11 Wall Street analysts rating Eli Lilly & Co, 5 give it “Buy”, 1 “Sell” rating, while 5 recommend “Hold”. The lowest target is $73.0 while the high is $105.0. The stock’s average target of $91.22 is 11.03% above today’s ($82.16) share price. LLY was included in 19 notes of analysts from October 27, 2017. Jefferies maintained the stock with “Buy” rating in Friday, March 23 report. BMO Capital Markets maintained it with “Underperform” rating and $74 target in Thursday, February 1 report. The stock of Eli Lilly and Company (NYSE:LLY) earned “Buy” rating by Jefferies on Tuesday, January 16. Morgan Stanley maintained the shares of LLY in report on Tuesday, November 21 with “Equal-Weight” rating. The rating was maintained by Jefferies on Monday, February 26 with “Buy”. Jefferies maintained Eli Lilly and Company (NYSE:LLY) rating on Thursday, November 16. Jefferies has “Buy” rating and $95.0 target. The firm earned “Hold” rating on Thursday, February 1 by Leerink Swann. BMO Capital Markets maintained the shares of LLY in report on Monday, November 13 with “Sell” rating. The company was maintained on Wednesday, December 13 by Credit Suisse. The company was maintained on Friday, April 13 by Jefferies.

Eli Lilly and Company (NYSE:LLY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: